We are developing antibodies to harness the anti-tumor activity of the immune system.
Cancer cells have the ability to produce molecules that inhibit how NK cells function, leading to tumor escape.
Monoclonal antibodies have been developed to prevent NK cell inactivation via the blocking of inhibitory checkpoint receptors at the surface of NK cells.
Monoclonal antibodies can also activate cells of the innate immune system, such as NK cells, and trigger an antibody-dependent cell-mediated cytotoxicity (ADCC), via NK cell activating receptors, such as CD16.
Multispecific antibodies can leverage activating checkpoints on NK cells to engage them against tumors. Our multispecific antibodies, also called NK cell engagers, bind to NKp46, with or without CD16, and the tumor antigen on the cancer cells. The co-engagement induces full NK cell activation and tumor cell lysis.
We have developed our propriety next generation multi-specific NKCE platform, ANKETTM (Antibody-based NK cell Engager Therapeutics), which we believe will be a key to discovering future wave of impactful clinical molecules in immunotherapy. Learn more about our ANKET platform.
Antibody drug conjugates (ADC)
ADCs are able to bring cytotoxic molecules (toxins) within the cancer cells by using antibodies as a carrier.
Our innovative coupling technology uses bacterial transglutaminase (BTG) enzyme that couples antibodies and drugs in a site-specific and precise stochiometry manner. It aims to address the heterogeneity of the coupling between the antibody and the drug of interest, heterogeneity that affects the therapeutic efficacy of antibody conjugates.